Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

BIO 2013 Wednesday Roundup: Roche Partnering, Crowdfunding, Alzheimer’s and Deal Trend Data

This article was originally published in The Pink Sheet Daily

Executive Summary

Our survey of news and notes from the third day of the BIO 2013 conference includes insights from panel discussions about the environments for licensing deals and Alzheimer’s disease research, an interview with a Roche exec about the company’s partnering strategy, and news about a crowdfunding portal that will connect VCs and companies with accredited individual investors.

You may also be interested in...



Deals Of The Week Watches Crowdfunders Multiply Like Rabbits

VentureHealth combines the best in venture and crowdfunding, and has two exits to show for it. Plus Valeant buys Bausch & Lomb, GSK buys Okairos, AZ buys Omthera, while ThromboGenics/Array, Pfizer/UCSF, and Amgen/Astellas do deals.

BIO 2013: Biosimilars, Drug Pricing, Business Development And Innovation

Pharma and biotech leaders discussed the biosimilars landscape, paying for innovation beyond rare disease drugs, emerging markets and partnering trends at BIO 2013 in Chicago.

Guidance For Drugs To Target Early Alzheimer’s Notes Lack Of Metrics, Biomarkers

FDA’s new draft guidance on developing drugs to treat people in the early stages of Alzheimer’s disease, before any noticeable dementia sets in, is sure to generate further discussion and comment on how best to identify and measure the disease and its progression.

Related Content

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

OM013164

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel